Key result
Omecamtiv mecarbil use in systolic heart failure was evaluated in the GALACTIC-HF trial to address the high global morbidity and mortality burden of the disease.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2021) studied this question. Omecamtiv mecarbil use in systolic heart failure was evaluated in the GALACTIC-HF trial to address the high global morbidity and mortality burden of the disease.
Synapse has enriched 10 related papers. Consider them for comparative context: